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The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy.
Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and
higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy of a
gentleman undergoing active surveillance leading to reclassiﬁcation of his disease as high risk prostate
cancer.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Active surveillance (AS) is one approach to reduce the
overtreatment of indolent prostate cancer and is increasingly
recognized as a primary management strategy for low-risk disease,
particularly among older men. While adoption of AS has risen
signiﬁcantly,1 there remains a lack of consensus regarding
monitoring strategies (i.e. the frequency of biopsy, imaging and
tumor marker ascertainment). The development of biomarkers for
clinically signiﬁcant prostate cancer can help guide patients and
providers, particularly those who elect to defer routine surveillance
biopsy.
At our institution, %free PSA has been routinely assessed in men
on active surveillance. Since 2015 some providers have opted to
utilize the Prostate Health Index (phi), which is calculated from total
PSA, free PSA, and [-2]proPSA (Beckman Coulter, Inc.), during
monitoring. Here we present the case of a gentleman on AS where
phi was used to recommend biopsy, which resulted in disease
reclassiﬁcation.arburg 134 Johns Hopkins
2101, USA. Tel.: þ1 410 955
Inc. This is an open access article uCase presentation
The patient presented in 2005 at age 73 due to an abnormal
rectal examination (clinical stage T2a) and serum PSA of
3.6 ng/mL. Twelve-core transrectal biopsy showed Gleason score
3 þ 3 ¼ 6 prostate cancer involving 20% of one core, and a prostate
volume of 66 cc (PSA density ¼ 0.05). As such, the patient was
diagnosed with NCCN low-risk prostate cancer. After appropriate
counseling with his provider, the patient elected to undergo
monitoring on AS.
Conﬁrmatory biopsy 1 year from diagnosis revealed Gleason
score 6 disease in 10% of one core, consistent with his diagnosis of
low-risk disease. Subsequent biopsies in 2007 and 2008 demon-
strated no evidence of cancer and his rectal exam was unchanged.
Although not consistent with our institutional AS protocol, at this
time the patient elected to defer annual biopsy in favor of serial PSA
and clinical examination.
Follow-up serum biomarker and prostate biopsy data are listed
in Table 1. In 2010, serum PSA was 2.7 ng/mL with 42.1% free PSA.
Subsequent PSA levels remained less than 4.0 ng/mL until a value of
5.6 ng/mL was detected in 2014 e 10 years after diagnosis (Fig. 1).
Follow-up testing in 2015 revealed a serum PSA of 10.4 ng/mL with
41.1% free PSA; an initial phi was obtained and found to equal 96.0.
Serum markers were conﬁrmed on a subsequent measure, and at
the insistence of his provider, the patient agreed to undergo repeat
biopsy, which revealed extensive cancer in 10 of 12 cores. Thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Biomarker measures during follow-up
2/2005 2/2006 2/2007 3/2008 9/2010 8/2011 9/2012 8/2013 8/2014 9/2015 10/2015
PSA total (ng/mL) 3.6 2.4 2.6 2.3 2.7 3.2 3.5 3.4 5.6 10.4 11.1
% free PSA 42.1 36.6a 38.1a 41.1 39.7
phi 32.9a 36.9a 96 99.6
Biopsy X X X X X
Volume 65.5 68.5 65 61.5 74
PSAD 0.05 0.04 0.04 0.04 0.15
a Indicates retrospective assessment of stored laboratory specimen.
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grade (i.e. Gleason score 8e10) disease. Bone and CT scans showed
no areas of uptake or lymphadenopathy concerning for metastasis.
The patient was offered localized treatment options and opted to
undergo radiation therapy.Discussion
Phi was FDA approved in 2013 to aid in decision-making
regarding prostate biopsy and has since become available for
clinical use.2 While phi has been associated with Gleason score,
non-organ conﬁned disease, and upgrading at radical prostatec-
tomy,2,3 there are limited data exploring the use of phi in an AS
population, particularly over long-term follow-up.4 We herein
report the case of a gentleman with disease reclassiﬁcation while
on surveillance which correlated with an elevation in his phi.
Several tools have been described to assist in clinical decision-
making for individuals such as this gentleman who elected to
defer routine surveillance biopsy. These tools include PSA kinetic
measures, % free PSA, prostate MRI, and urinary biomarkers.4,5
Fluctuations in PSA during surveillance have not been shown to
reliably predict reclassiﬁcation,6 although in some instances rapid
PSA doubling can indicate disease progression.4 Percent free PSA
and PSA density have also been used to assess risk during
surveillance. This case points out limitations in the use of theseFigure 1. Trends in biomarker mmetrics, given the patient’s free PSA remained extremely favorable
at over 35%, and his PSA density was 0.15 at its highest value.
Contrary to the free PSA, the phi value of 96.0 best reﬂected the
higher-grade cancer present at the time of assessment. This begs the
question as to whether earlier phi measures could have prevented
this adverse outcome and suggests an area for further study.
Certainly, additional research is necessary to better understand
cases in which available biomarkers are discordant, as well as to
identify those cases inwhich one marker could prove optimal. Until
these and other non-invasive tools are tested and validated in the AS
population, this case further supports the necessity of more inten-
sive monitoring techniques such as repeat prostate biopsy.Conclusion
The utility of phi and other non-invasive markers in the AS
setting remains unclear, largely secondary to a lack of long-term
data. There is hope that combining these markers with other
tools such as multiparametric MRI may allow for a less-invasive
approach to monitoring men with prostate cancer. Until an alter-
native approach is validated, however, we must acknowledge the
substantial risk associated with deferring prostate biopsy over an
extended period.Conﬂicts of interest
The authors declare no conﬂicts of interest.easures during follow-up.
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